A new biomarker that predicts ventricular arrhythmia in patients with ischemic dilated cardiomyopathy: Galectin-3

Introduction: Ventricular arrhythmias are caused by scar tissue in patients with ischemic dilated cardiomyopathy. The gold standard imaging technique for detecting scar tissue is magnetic resonance imaging (MRI). However, MRI is not feasible for use as a screening test, and also cannot be used in pa...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Onur Erdogan, Ekrem Karaayvaz, Tugba Erdogan, Cafer Panc, Remzi Sarıkaya, Aytac Oncul, Ahmet Kaya Bilge
Formato:	article
Lenguaje:	EN PT
Publicado:	Elsevier 2021
Materias:	Galectina-3 Miocardiopatia isquémica dilatada Cardioversor-desfibrilhador implantável Arritmia ventricular Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/92b05e1b87da4bd79a31903ec705563c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:92b05e1b87da4bd79a31903ec705563c
record_format	dspace
institution	DOAJ
collection	DOAJ
language	EN PT
topic	Galectina-3 Miocardiopatia isquémica dilatada Cardioversor-desfibrilhador implantável Arritmia ventricular Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	Galectina-3 Miocardiopatia isquémica dilatada Cardioversor-desfibrilhador implantável Arritmia ventricular Diseases of the circulatory (Cardiovascular) system RC666-701 Onur Erdogan Ekrem Karaayvaz Tugba Erdogan Cafer Panc Remzi Sarıkaya Aytac Oncul Ahmet Kaya Bilge A new biomarker that predicts ventricular arrhythmia in patients with ischemic dilated cardiomyopathy: Galectin-3
description	Introduction: Ventricular arrhythmias are caused by scar tissue in patients with ischemic dilated cardiomyopathy. The gold standard imaging technique for detecting scar tissue is magnetic resonance imaging (MRI). However, MRI is not feasible for use as a screening test, and also cannot be used in patients who have received an implantable cardioverter-defibrillator (ICD). In this study, we aimed to assess the association between levels of galectin-3 (Gal-3), which is known to be secreted by scar tissue, and the history of ventricular arrhythmias in patients with ischemic dilated cardiomyopathy who received an ICD. Methods: Nineteen healthy controls and 32 patients who had previously undergone VVI-ICD implantation due to ischemic dilated cardiomyopathy were enrolled in the study. Patients were divided into three groups: the first group including patients who had received no ICD therapies, the second including patients with arrhythmia requiring therapies with no arrhythmia storm, and the third including patients who had arrhythmia storm. We assessed the association between Gal-3 levels and the history of ventricular arrhythmias in these patients. Results: Gal-3 levels were significantly higher in the patient groups than in the control group (p<0.01). Gal-3 levels of patients with arrhythmias requiring ICD therapies were significantly higher than in patients with ICD not requiring therapies (p=0.02). They were also higher in patients with a history of arrhythmia storm than in patients without shocks (p=0.05). Receiver operating curve analysis showed with 84% sensitivity and 75% specificity that Gal-3 levels over 7 ng/ml indicated ventricular arrhythmia that required therapies. Conclusion: Gal-3 may be used to further improve risk stratification in patients with ischemic cardiomyopathy who are more prone to developing life-threatening arrhythmias. Resumo: Introdução: Em doentes com miocardiopatia isquémica dilatada as arritmias ventriculares são causadas por tecidos cicatriciais. O gold standard das técnicas de imagem na deteção de fibrose é a ressonância magnética (RM). No entanto, esta não é viável como teste de rastreio e também não pode ser utilizada em muitos doentes com cardioversor desfibrilhador implantável (CDI). Neste estudo, pretendemos avaliar a associação entre o nível de Galectina-3 (Gal-3), que é secretada por tecidos cicatriciais, e a história de arritmias ventriculares em doentes com miocardiopatia isquémica dilatada com CDI implantado. Métodos: Dezanove casos controlo saudáveis e 32 doentes, previamente submetidos a implantação de CDI-VVI por miocardiopatia isquémica dilatada, foram incluídos. Os doentes foram divididos em três grupos. O primeiro grupo incluiu doentes que não se submeteram a tratamento. O segundo grupo incluiu doentes com arritmias que necessitaram de tratamento mas sem tempestade arritmica. O último grupo incluiu doentes com tempestades arrítmicas. Avaliámos a associação entre os níveis de Gal-3 e a história de arritmias ventriculares naqueles doentes. Resultados: O nível de Gal-3 foi significativamente mais elevado no grupo de doentes do que no grupo controlo (<0,01). Os níveis de Gal-3 nos doentes com arritmias que necessitaram de tratamento com CDI foram significativamente mais elevados do que nos doentes com CDI que não necessitaram de tratamento (p: 0,02). Os níveis de Gal-3 foram mais elevados nos doentes com detempestade arrítmica do que nos doentes sem choques (p: 0,05). Verificámos nas análises ROC, com sensibilidade de 84% e com especificidade de 75%, que níveis de Gal-3 acima de 7 ng/mL são preditores de arritmia ventricular que requer tratamento. Conclusão: A Gal-3 pode ser utilizada para melhorar a estratificação de risco em doentes com miocardiopatia isquémica dilatada, identificando os doentes com maior propensão a desenvolver arritmias ventriculares malignas.
format	article
author	Onur Erdogan Ekrem Karaayvaz Tugba Erdogan Cafer Panc Remzi Sarıkaya Aytac Oncul Ahmet Kaya Bilge
author_facet	Onur Erdogan Ekrem Karaayvaz Tugba Erdogan Cafer Panc Remzi Sarıkaya Aytac Oncul Ahmet Kaya Bilge
author_sort	Onur Erdogan
title	A new biomarker that predicts ventricular arrhythmia in patients with ischemic dilated cardiomyopathy: Galectin-3
title_short	A new biomarker that predicts ventricular arrhythmia in patients with ischemic dilated cardiomyopathy: Galectin-3
title_full	A new biomarker that predicts ventricular arrhythmia in patients with ischemic dilated cardiomyopathy: Galectin-3
title_fullStr	A new biomarker that predicts ventricular arrhythmia in patients with ischemic dilated cardiomyopathy: Galectin-3
title_full_unstemmed	A new biomarker that predicts ventricular arrhythmia in patients with ischemic dilated cardiomyopathy: Galectin-3
title_sort	new biomarker that predicts ventricular arrhythmia in patients with ischemic dilated cardiomyopathy: galectin-3
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/92b05e1b87da4bd79a31903ec705563c
work_keys_str_mv	AT onurerdogan anewbiomarkerthatpredictsventriculararrhythmiainpatientswithischemicdilatedcardiomyopathygalectin3 AT ekremkaraayvaz anewbiomarkerthatpredictsventriculararrhythmiainpatientswithischemicdilatedcardiomyopathygalectin3 AT tugbaerdogan anewbiomarkerthatpredictsventriculararrhythmiainpatientswithischemicdilatedcardiomyopathygalectin3 AT caferpanc anewbiomarkerthatpredictsventriculararrhythmiainpatientswithischemicdilatedcardiomyopathygalectin3 AT remzisarıkaya anewbiomarkerthatpredictsventriculararrhythmiainpatientswithischemicdilatedcardiomyopathygalectin3 AT aytaconcul anewbiomarkerthatpredictsventriculararrhythmiainpatientswithischemicdilatedcardiomyopathygalectin3 AT ahmetkayabilge anewbiomarkerthatpredictsventriculararrhythmiainpatientswithischemicdilatedcardiomyopathygalectin3 AT onurerdogan newbiomarkerthatpredictsventriculararrhythmiainpatientswithischemicdilatedcardiomyopathygalectin3 AT ekremkaraayvaz newbiomarkerthatpredictsventriculararrhythmiainpatientswithischemicdilatedcardiomyopathygalectin3 AT tugbaerdogan newbiomarkerthatpredictsventriculararrhythmiainpatientswithischemicdilatedcardiomyopathygalectin3 AT caferpanc newbiomarkerthatpredictsventriculararrhythmiainpatientswithischemicdilatedcardiomyopathygalectin3 AT remzisarıkaya newbiomarkerthatpredictsventriculararrhythmiainpatientswithischemicdilatedcardiomyopathygalectin3 AT aytaconcul newbiomarkerthatpredictsventriculararrhythmiainpatientswithischemicdilatedcardiomyopathygalectin3 AT ahmetkayabilge newbiomarkerthatpredictsventriculararrhythmiainpatientswithischemicdilatedcardiomyopathygalectin3
_version_	1718429969897488384
spelling	oai:doaj.org-article:92b05e1b87da4bd79a31903ec705563c2021-11-14T04:30:41ZA new biomarker that predicts ventricular arrhythmia in patients with ischemic dilated cardiomyopathy: Galectin-30870-255110.1016/j.repc.2020.12.013https://doaj.org/article/92b05e1b87da4bd79a31903ec705563c2021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S087025512100384Xhttps://doaj.org/toc/0870-2551Introduction: Ventricular arrhythmias are caused by scar tissue in patients with ischemic dilated cardiomyopathy. The gold standard imaging technique for detecting scar tissue is magnetic resonance imaging (MRI). However, MRI is not feasible for use as a screening test, and also cannot be used in patients who have received an implantable cardioverter-defibrillator (ICD). In this study, we aimed to assess the association between levels of galectin-3 (Gal-3), which is known to be secreted by scar tissue, and the history of ventricular arrhythmias in patients with ischemic dilated cardiomyopathy who received an ICD. Methods: Nineteen healthy controls and 32 patients who had previously undergone VVI-ICD implantation due to ischemic dilated cardiomyopathy were enrolled in the study. Patients were divided into three groups: the first group including patients who had received no ICD therapies, the second including patients with arrhythmia requiring therapies with no arrhythmia storm, and the third including patients who had arrhythmia storm. We assessed the association between Gal-3 levels and the history of ventricular arrhythmias in these patients. Results: Gal-3 levels were significantly higher in the patient groups than in the control group (p<0.01). Gal-3 levels of patients with arrhythmias requiring ICD therapies were significantly higher than in patients with ICD not requiring therapies (p=0.02). They were also higher in patients with a history of arrhythmia storm than in patients without shocks (p=0.05). Receiver operating curve analysis showed with 84% sensitivity and 75% specificity that Gal-3 levels over 7 ng/ml indicated ventricular arrhythmia that required therapies. Conclusion: Gal-3 may be used to further improve risk stratification in patients with ischemic cardiomyopathy who are more prone to developing life-threatening arrhythmias. Resumo: Introdução: Em doentes com miocardiopatia isquémica dilatada as arritmias ventriculares são causadas por tecidos cicatriciais. O gold standard das técnicas de imagem na deteção de fibrose é a ressonância magnética (RM). No entanto, esta não é viável como teste de rastreio e também não pode ser utilizada em muitos doentes com cardioversor desfibrilhador implantável (CDI). Neste estudo, pretendemos avaliar a associação entre o nível de Galectina-3 (Gal-3), que é secretada por tecidos cicatriciais, e a história de arritmias ventriculares em doentes com miocardiopatia isquémica dilatada com CDI implantado. Métodos: Dezanove casos controlo saudáveis e 32 doentes, previamente submetidos a implantação de CDI-VVI por miocardiopatia isquémica dilatada, foram incluídos. Os doentes foram divididos em três grupos. O primeiro grupo incluiu doentes que não se submeteram a tratamento. O segundo grupo incluiu doentes com arritmias que necessitaram de tratamento mas sem tempestade arritmica. O último grupo incluiu doentes com tempestades arrítmicas. Avaliámos a associação entre os níveis de Gal-3 e a história de arritmias ventriculares naqueles doentes. Resultados: O nível de Gal-3 foi significativamente mais elevado no grupo de doentes do que no grupo controlo (<0,01). Os níveis de Gal-3 nos doentes com arritmias que necessitaram de tratamento com CDI foram significativamente mais elevados do que nos doentes com CDI que não necessitaram de tratamento (p: 0,02). Os níveis de Gal-3 foram mais elevados nos doentes com detempestade arrítmica do que nos doentes sem choques (p: 0,05). Verificámos nas análises ROC, com sensibilidade de 84% e com especificidade de 75%, que níveis de Gal-3 acima de 7 ng/mL são preditores de arritmia ventricular que requer tratamento. Conclusão: A Gal-3 pode ser utilizada para melhorar a estratificação de risco em doentes com miocardiopatia isquémica dilatada, identificando os doentes com maior propensão a desenvolver arritmias ventriculares malignas.Onur ErdoganEkrem KaraayvazTugba ErdoganCafer PancRemzi SarıkayaAytac OnculAhmet Kaya BilgeElsevierarticleGalectina-3Miocardiopatia isquémica dilatadaCardioversor-desfibrilhador implantávelArritmia ventricularDiseases of the circulatory (Cardiovascular) systemRC666-701ENPTRevista Portuguesa de Cardiologia, Vol 40, Iss 11, Pp 829-835 (2021)

A new biomarker that predicts ventricular arrhythmia in patients with ischemic dilated cardiomyopathy: Galectin-3

Ejemplares similares